细胞免疫治疗药物研发商NKGen Biotec宣布SNK01 NK细胞疗法的IND申请获FDA批准

NKGen Biotech: FDA Clears IND Application For SNK01 NK Cell Therapy

RTTNews | 2024-04-29 | 翻译由动脉网AI生成，点击反馈



可切换为仅中文







NKGen Biotech, Inc. (NKGN) announced the FDA has cleared the company's IND application for SNK01 NK cell therapy for the treatment of Parkinson's disease. SNK01 is an autologous, nongenetically modified NK cell product.The IND clearance enables the company to initiate a Phase 1/2a clinical trial evaluating the safety, tolerability, and exploratory efficacy of SNK01 in patients with PD.

NKGen Biotech，Inc.（NKGN）宣布，FDA已批准该公司针对SNK01 NK细胞治疗帕金森病的IND申请。SNK01是一种自体，非遗传修饰的NK细胞产物。IND清除率使该公司能够启动1/2a期临床试验，评估SNK01在PD患者中的安全性，耐受性和探索性疗效。

The trial is designed to enroll up to 30 patients. NKGen expects to begin the trial, with the first patient dosed, in the second half of 2024.For More Such Health News, visit rttnews.com. For comments and feedback contact: editorial@rttnews.comBusiness News.

该试验旨在招募多达30名患者。NKGen预计在2024年下半年开始试验，第一名患者服用。有关更多此类健康新闻，请访问rttnews.com。有关评论和反馈，请联系：editorial@rttnews.comBusiness新闻。